IMRN

Key Points Immuron Engages Pullan Consulting to Advance IMM-529 Partnering Strategy Immuron is seeking a partner to support clinical development through regulatory approval and commercialization Immuron has U.S. Food and Drug administration (FDA) approval for IMM-529 Investigational New Drug (IND) application IND 32095 is Immuron's Investigational new drug (IND) application for clinical development of IMM-529 as a product to specifically prevent or treat Clostridioides difficile infection (CDI) MELBOURNE, Australia, July 06, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to announce that it has engaged Pullan Consulting to provide business development services to assist in securing a strategic partnership for IMM-529. Pullan Consulting is a highly regarded life sciences advisory firm with a strong track record of executing between five and twelve partnering transactions annually over the past 20 years.

NEW YORK CITY, NY / ACCESS Newswire / April 22, 2026 / Emerging Growth Research today released a Flash Report on Immuron (Nasdaq:IMRN), maintaining its Buy-Extended rating while increasing its 12-month price target to $4.00 (from $3.90), representing significant upside from the current share price of $0.9268 as of April 21, 2026. The Flash Report highlights Immuron's continued revenue growth, expanding commercial footprint, and progress within its clinical development pipeline.

Sales Highlights (unaudited): Global Q3 sales AUD$1.5 million up 16% on prior comparative period (pcp) YTD Mar 2026 sales AUD$5.7 million up 7% on prior comparative period (pcp) Australia Q3 sales AUD$0.9 million up 15% on prior comparative period (pcp) YTD Mar 2026 sales AUD$4.2 million up 14% on prior comparative period (pcp) Canada Q3 sales AUD$0.1 million up >100% on prior comparative period (pcp) Q3 sales up 82% on prior quarter; initial sales to Jean Coutu, Quebec YTD Mar 2026 sales AUD$0.1 million down 65% on prior comparative period (pcp) USA Q3 sales AUD$0.5 million up 1% on prior comparative period (pcp) YTD Mar 2026 sales AUD$1.3 million up 10% on prior comparative period (pcp) MELBOURNE, Australia, April 17, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract. Continued Travelan® Q3 sales growth ( +15% on pcp) in Australia can be contributed to: (1) increased awareness and consideration driven by extensive digital and social media marketing.